Momenta Pharmaceuticals (NASDAQ: MNTA) and Idera Pharmaceuticals (NASDAQ:IDRA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership and dividends.
This table compares Momenta Pharmaceuticals and Idera Pharmaceuticals’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Volatility & Risk
Momenta Pharmaceuticals has a beta of 1.8, indicating that its share price is 80% more volatile than the S&P 500. Comparatively, Idera Pharmaceuticals has a beta of 2.2, indicating that its share price is 120% more volatile than the S&P 500.
Valuation and Earnings
This table compares Momenta Pharmaceuticals and Idera Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.
||Earnings Per Share
Momenta Pharmaceuticals has higher revenue and earnings than Idera Pharmaceuticals. Momenta Pharmaceuticals is trading at a lower price-to-earnings ratio than Idera Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
This is a summary of current recommendations and price targets for Momenta Pharmaceuticals and Idera Pharmaceuticals, as provided by MarketBeat.com.
||Strong Buy Ratings
Momenta Pharmaceuticals currently has a consensus target price of $14.78, indicating a potential downside of 7.06%. Idera Pharmaceuticals has a consensus target price of $5.40, indicating a potential upside of 200.00%. Given Idera Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Idera Pharmaceuticals is more favorable than Momenta Pharmaceuticals.
Institutional and Insider Ownership
93.1% of Momenta Pharmaceuticals shares are owned by institutional investors. Comparatively, 24.1% of Idera Pharmaceuticals shares are owned by institutional investors. 4.4% of Momenta Pharmaceuticals shares are owned by company insiders. Comparatively, 12.4% of Idera Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Idera Pharmaceuticals beats Momenta Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
Momenta Pharmaceuticals Company Profile
Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection). GLATOPA 20 milligrams (mg)/ milliliters (mL) is a generic version of once-daily COPAXONE 20 mg/mL indicated for the treatment of patients with relapsing forms of multiple sclerosis, a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. COPAXONE is available in both a once-daily 20 mg/mL formulation and a three-times-weekly 40 mg/mL formulation. The Company’s Enoxaparin Sodium Injection is a generic version of LOVENOX indicated for the prevention and treatment of deep vein thrombosis and to support the treatment of acute coronary syndromes. The Company’s programs include M254, M281 (Anti-FcRn candidate) and M230.
Idera Pharmaceuticals Company Profile
Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology. Using TLR technology, the Company designs synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. Using its 3GA technology, the Company is developing drug candidates to turn off the messenger ribo nucleic acid (mRNA) associated with disease causing genes. The Company’s drug candidates include IMO-8400, IMO-2125 and IMO-9200. The Company has designed TLR antagonists and agonists to act by modulating the activity of targeted TLRs. It is developing its 3GA technology to turn off the mRNA associated with disease causing genes.
Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.